2023 至 2024 年间奥罗普切病毒在巴西再次出现

BSc Gabriel C. Scachetti, BSc Julia Forato, PhD Ingra M. Claro, Xinyi Hua, DrPH, PhD Bárbara B. Salgado, MSc Aline Vieira, BSc Camila L. Simeoni, PhD Aguyda R C. Barbosa, BSc Italo L. Rosa, PhD Gabriela F. de Souza, Luana C. N. Fernandes BSc, Ana Carla, BSc H. de Sena, BSc Stephanne C. Oliveira, PhD Carolina M. L. Singh, PhD Shirlene T. de Lima, PhD Ronaldo de Jesus, PhD Mariana A. Costa, PhD Rodrigo B Kato, BSc Josilene F. Rocha, BSc Leandro C. Santos, PhD Janete T. Rodrigues, PhD Marielton P. Cunha, MD PhD Ester C. Sabino, PhD Nuno R. Faria, PhD Scott C Weaver, PhD Camila M. Romano, Dr rer nat Pritesh Lalwani, PhD José Luiz Proença-Módena, PhD William M. de Souza
{"title":"2023 至 2024 年间奥罗普切病毒在巴西再次出现","authors":"BSc Gabriel C. Scachetti, BSc Julia Forato, PhD Ingra M. Claro, Xinyi Hua, DrPH, PhD Bárbara B. Salgado, MSc Aline Vieira, BSc Camila L. Simeoni, PhD Aguyda R C. Barbosa, BSc Italo L. Rosa, PhD Gabriela F. de Souza, Luana C. N. Fernandes BSc, Ana Carla, BSc H. de Sena, BSc Stephanne C. Oliveira, PhD Carolina M. L. Singh, PhD Shirlene T. de Lima, PhD Ronaldo de Jesus, PhD Mariana A. Costa, PhD Rodrigo B Kato, BSc Josilene F. Rocha, BSc Leandro C. Santos, PhD Janete T. Rodrigues, PhD Marielton P. Cunha, MD PhD Ester C. Sabino, PhD Nuno R. Faria, PhD Scott C Weaver, PhD Camila M. Romano, Dr rer nat Pritesh Lalwani, PhD José Luiz Proença-Módena, PhD William M. de Souza","doi":"10.1101/2024.07.27.24310296","DOIUrl":null,"url":null,"abstract":"Background: Oropouche virus (OROV; species Orthobunyavirus oropoucheense) is an arthropod-borne virus that has caused outbreaks of Oropouche fever in Central and South America since the 1950s. This study investigates virological factors contributing to the reemergence of Oropouche fever in Brazil between 2023 and 2024. Methods: In this study, we combined OROV genomic, molecular, and serological data from Brazil from 1 January 2015 to 29 June 2024, along with in vitro and in vivo characterization. Molecular screening data included 234 patients with febrile illness or central nervous system (CNS) manifestations between December 2023 and May 2024 from the Amazonas State. Genomic data comprised two genomic OROV sequences from patients. Serological data were obtained from neutralizing antibody tests comparing the prototype OROV strain BeAn 19991 and the 2024 epidemic strain. Epidemiological data included aggregated cases reported to the Brazilian Ministry of Health from 1 January 2014 to 29 June 2024. Findings: In 2024, autochthonous OROV infections were detected in previously non-endemic areas across all five Brazilian regions. Cases were reported in 19 of 27 federal units, with 83.2% (6,895 of 8,284) of infections in Northern Brazil and a nearly 200-fold increase in incidence compared to reported cases over the last decade. We detected OROV RNA in 10.8% (10 of 93) of patients with febrile illness and 2.1% (3 of 141) of patients with CNS manifestations between December 2023 and May 2024 in Amazonas. We demonstrate that the 2023-2024 epidemic was caused by a novel OROV reassortant that replicated approximately 100-fold higher titers in mammalian cells compared to the prototype strain. The 2023-2024 OROV reassortant displayed plaques earlier than the prototype, produced 1.7 times more plaques, and plaque sizes were 2.5 larger compared to the prototype. Furthermore, serum collected in 2016 from previously OROV-infected individuals showed at least a 32-fold reduction in neutralizing capacity against the reassortment strain compared to the prototype. Interpretation: These findings provide a comprehensive assessment of Oropouche fever in Brazil and contribute to a better understanding of the 2023-2024 OROV reemergence. The recent increased incidence may be related to a higher replication efficiency of a new reassortant virus that also evades previous immunity.","PeriodicalId":506788,"journal":{"name":"medRxiv","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reemergence of Oropouche virus between 2023 and 2024 in Brazil\",\"authors\":\"BSc Gabriel C. Scachetti, BSc Julia Forato, PhD Ingra M. Claro, Xinyi Hua, DrPH, PhD Bárbara B. Salgado, MSc Aline Vieira, BSc Camila L. Simeoni, PhD Aguyda R C. Barbosa, BSc Italo L. Rosa, PhD Gabriela F. de Souza, Luana C. N. Fernandes BSc, Ana Carla, BSc H. de Sena, BSc Stephanne C. Oliveira, PhD Carolina M. L. Singh, PhD Shirlene T. de Lima, PhD Ronaldo de Jesus, PhD Mariana A. Costa, PhD Rodrigo B Kato, BSc Josilene F. Rocha, BSc Leandro C. Santos, PhD Janete T. Rodrigues, PhD Marielton P. Cunha, MD PhD Ester C. Sabino, PhD Nuno R. Faria, PhD Scott C Weaver, PhD Camila M. Romano, Dr rer nat Pritesh Lalwani, PhD José Luiz Proença-Módena, PhD William M. de Souza\",\"doi\":\"10.1101/2024.07.27.24310296\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Oropouche virus (OROV; species Orthobunyavirus oropoucheense) is an arthropod-borne virus that has caused outbreaks of Oropouche fever in Central and South America since the 1950s. This study investigates virological factors contributing to the reemergence of Oropouche fever in Brazil between 2023 and 2024. Methods: In this study, we combined OROV genomic, molecular, and serological data from Brazil from 1 January 2015 to 29 June 2024, along with in vitro and in vivo characterization. Molecular screening data included 234 patients with febrile illness or central nervous system (CNS) manifestations between December 2023 and May 2024 from the Amazonas State. Genomic data comprised two genomic OROV sequences from patients. Serological data were obtained from neutralizing antibody tests comparing the prototype OROV strain BeAn 19991 and the 2024 epidemic strain. Epidemiological data included aggregated cases reported to the Brazilian Ministry of Health from 1 January 2014 to 29 June 2024. Findings: In 2024, autochthonous OROV infections were detected in previously non-endemic areas across all five Brazilian regions. Cases were reported in 19 of 27 federal units, with 83.2% (6,895 of 8,284) of infections in Northern Brazil and a nearly 200-fold increase in incidence compared to reported cases over the last decade. We detected OROV RNA in 10.8% (10 of 93) of patients with febrile illness and 2.1% (3 of 141) of patients with CNS manifestations between December 2023 and May 2024 in Amazonas. We demonstrate that the 2023-2024 epidemic was caused by a novel OROV reassortant that replicated approximately 100-fold higher titers in mammalian cells compared to the prototype strain. The 2023-2024 OROV reassortant displayed plaques earlier than the prototype, produced 1.7 times more plaques, and plaque sizes were 2.5 larger compared to the prototype. Furthermore, serum collected in 2016 from previously OROV-infected individuals showed at least a 32-fold reduction in neutralizing capacity against the reassortment strain compared to the prototype. Interpretation: These findings provide a comprehensive assessment of Oropouche fever in Brazil and contribute to a better understanding of the 2023-2024 OROV reemergence. The recent increased incidence may be related to a higher replication efficiency of a new reassortant virus that also evades previous immunity.\",\"PeriodicalId\":506788,\"journal\":{\"name\":\"medRxiv\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.07.27.24310296\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.07.27.24310296","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:奥罗普切病毒(OROV;Orthobunyavirus oropoucheense的一种)是一种节肢动物传播的病毒,自20世纪50年代以来曾在中美洲和南美洲爆发过奥罗普切热。本研究调查了导致 2023 年至 2024 年巴西再次出现奥罗普切热的病毒学因素。研究方法在这项研究中,我们结合了 2015 年 1 月 1 日至 2024 年 6 月 29 日期间巴西的 OROV 基因组、分子和血清学数据,以及体外和体内特征描述。分子筛查数据包括亚马孙州2023年12月至2024年5月期间234名发热疾病或中枢神经系统(CNS)表现的患者。基因组数据包括患者的两个基因组 OROV 序列。血清学数据来自中和抗体测试,比较了原型 OROV 菌株 BeAn 19991 和 2024 年流行的菌株。流行病学数据包括2014年1月1日至2024年6月29日向巴西卫生部报告的病例总数。研究结果2024 年,巴西所有五个大区都在以前未流行的地区发现了自体 OROV 感染病例。27个联邦单位中有19个报告了病例,83.2%的感染病例(8,284例中的6,895例)发生在北巴西,与过去十年报告的病例相比,发病率增加了近200倍。2023年12月至2024年5月期间,我们在亚马孙地区10.8%的发热病人(93人中有10人)和2.1%的中枢神经系统表现病人(141人中有3人)中检测到了OROV RNA。我们证明,2023-2024 年的疫情是由新型 OROV 重变种引起的,与原型菌株相比,它在哺乳动物细胞中的复制滴度高出约 100 倍。与原型菌株相比,2023-2024 年的 OROV 重变种比原型菌株更早出现斑块,产生的斑块数量是原型菌株的 1.7 倍,斑块大小也比原型菌株大 2.5 倍。此外,2016年从以前感染过OROV的人身上采集的血清显示,与原型相比,对重配株的中和能力至少降低了32倍。解读:这些发现全面评估了巴西的奥罗波切热,有助于更好地了解2023-2024年奥罗波切热再次爆发的情况。最近发病率的上升可能与一种新的重配病毒复制效率较高有关,这种病毒也能逃避以前的免疫。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Reemergence of Oropouche virus between 2023 and 2024 in Brazil
Background: Oropouche virus (OROV; species Orthobunyavirus oropoucheense) is an arthropod-borne virus that has caused outbreaks of Oropouche fever in Central and South America since the 1950s. This study investigates virological factors contributing to the reemergence of Oropouche fever in Brazil between 2023 and 2024. Methods: In this study, we combined OROV genomic, molecular, and serological data from Brazil from 1 January 2015 to 29 June 2024, along with in vitro and in vivo characterization. Molecular screening data included 234 patients with febrile illness or central nervous system (CNS) manifestations between December 2023 and May 2024 from the Amazonas State. Genomic data comprised two genomic OROV sequences from patients. Serological data were obtained from neutralizing antibody tests comparing the prototype OROV strain BeAn 19991 and the 2024 epidemic strain. Epidemiological data included aggregated cases reported to the Brazilian Ministry of Health from 1 January 2014 to 29 June 2024. Findings: In 2024, autochthonous OROV infections were detected in previously non-endemic areas across all five Brazilian regions. Cases were reported in 19 of 27 federal units, with 83.2% (6,895 of 8,284) of infections in Northern Brazil and a nearly 200-fold increase in incidence compared to reported cases over the last decade. We detected OROV RNA in 10.8% (10 of 93) of patients with febrile illness and 2.1% (3 of 141) of patients with CNS manifestations between December 2023 and May 2024 in Amazonas. We demonstrate that the 2023-2024 epidemic was caused by a novel OROV reassortant that replicated approximately 100-fold higher titers in mammalian cells compared to the prototype strain. The 2023-2024 OROV reassortant displayed plaques earlier than the prototype, produced 1.7 times more plaques, and plaque sizes were 2.5 larger compared to the prototype. Furthermore, serum collected in 2016 from previously OROV-infected individuals showed at least a 32-fold reduction in neutralizing capacity against the reassortment strain compared to the prototype. Interpretation: These findings provide a comprehensive assessment of Oropouche fever in Brazil and contribute to a better understanding of the 2023-2024 OROV reemergence. The recent increased incidence may be related to a higher replication efficiency of a new reassortant virus that also evades previous immunity.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Reemergence of Oropouche virus between 2023 and 2024 in Brazil Towards Personalized Breast Cancer Risk Management: A Thai Cohort Study on Polygenic Risk Scores Hot Spring Residency and Disease Association: a Crossover Gene-Environment Interaction (GxE) Study in Taiwan Evaluation of the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in renal cancer Dual exposure-by-polygenic score interactions highlight disparities across social groups in the proportion needed to benefit
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1